16-Jan-2019

**Medicinal products containing carbimazole or thiamazole (synonym: methimazole): (1) strengthened advice on contraception and (2) risk of acute pancreatitis**

Dear Healthcare professional,

Amdipharm Limited and Essential-Healthcare Ltd in agreement with the European Medicines Agency and the Health Products Regulatory Authority (HPRA) would like to inform you of the following:

**Summary**

(1) **Strengthened advice on contraception**

- New review of available evidence from epidemiological studies and case reports strengthens the evidence that carbimazole/thiamazole is suspected to cause congenital malformations when administered during pregnancy, particularly in the first trimester of pregnancy and at high doses.

- Women of childbearing potential have to use effective contraceptive measures during treatment with carbimazole/thiamazole.

- Hyperthyroidism in pregnant women should be adequately treated to prevent serious maternal and foetal complications.

- Carbimazole/thiamazole must only be administered during pregnancy after a strict individual benefit/risk assessment and only at the lowest effective dose without additional administration of thyroid hormones.

- If carbimazole/thiamazole is used during pregnancy, close maternal, foetal and neonatal monitoring is recommended.

(2) **Risk of acute pancreatitis**

- Acute pancreatitis has been reported following treatment with carbimazole/thiamazole.

- If acute pancreatitis occurs, treatment with carbimazole/thiamazole should be discontinued immediately.

- As re-exposure may result in recurrence of acute pancreatitis, with decreased time to onset, these medicines must not be given to patients with a history of acute pancreatitis following administration of carbimazole/thiamazole.

**Background on the safety concern**

**General information**

Medicinal products containing carbimazole or thiamazole are used in the management of hyperthyroidism, preparation for thyroidectomy in hyperthyroidism and therapy prior to and post radio-iodine treatment.
Carbimazole is a prodrug which undergoes rapid metabolism to the active metabolite, thiamazole. Thiamazole is an antithyroid agent that acts by blocking the production of thyroid hormones.

**Strengthened advice on contraception**

A new review of available evidence from epidemiological studies and case reports strengthens the evidence that carbimazole/thiamazole can be associated with an increased risk of congenital malformations, especially when administered in the first trimester of pregnancy and at high doses.

Reported malformations include aplasia cutis congenita (absence of a portion of skin (often localised on the head)), craniofacial malformations (choanal atresia; facial dysmorphism), defects of the abdominal wall and gastrointestinal tract (exomphalos, oesophageal atresia, omphalo-mesenteric duct anomaly), and ventricular septal defect.

**Recommendations**

It is therefore recommended that women of childbearing potential use effective contraceptive measures during treatment with carbimazole/thiamazole.

The use of carbimazole/thiamazole during pregnancy should be preserved for the situations in which a definitive therapy of the underlying disease (thyroidectomy or radioiodine treatment) was not suitable prior to pregnancy and in case of new occurrence or reoccurrence during pregnancy.

Carbimazole/thiamazole must only be administered during pregnancy after a strict individual benefit/risk assessment and only at the lowest effective dose without additional administration of thyroid hormones.

If carbimazole/thiamazole is used during pregnancy, close maternal, foetal and neonatal monitoring is recommended.

The product information for medicinal products containing carbimazole/thiamazole will be updated accordingly.

**Risk of acute pancreatitis**

There have been post-marketing reports of acute pancreatitis with the use of medicinal products containing carbimazole/thiamazole.

While the mechanism is poorly understood, the presence of cases reporting recurrent acute pancreatitis with a decreased time to onset after re-exposure to carbimazole/thiamazole might suggest an immunological mechanism.

Immediate discontinuation of medicinal products containing carbimazole/thiamazole is required in patients who develop acute pancreatitis following exposure to carbimazole or thiamazole. Carbimazole/thiamazole must not be restarted, and affected patients should be switched to an alternative therapy on the basis of the individual benefit/risk assessment.

Any future re-exposure to carbimazole/thiamazole in patients who have experienced acute pancreatitis with carbimazole or thiamazole in the past must be avoided, since it may result in recurrence of potentially life-threatening acute pancreatitis, with decreased time to onset.

The product information for medicinal products containing carbimazole/thiamazole will be updated accordingly.

**Call for reporting**

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:
HPRA Pharmacovigilance, Earlsfort Terrace, IRL-Dublin 2;
Tel: +3531 6764971
Fax: +3531 6762517
Website: www.hpra.ie

Suspected adverse reactions may also be reported to the companies via the contact details listed in the table below.

<table>
<thead>
<tr>
<th>Company name</th>
<th>Product Name</th>
<th>E-mail</th>
<th>Telephone number</th>
<th>Fax Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amdipharm Limited</td>
<td>NeoMerazole 5 mg Tablets &amp; NeoMercazole 20 mg Tablets</td>
<td><a href="mailto:medicalinformation@advanzpharma.com">medicalinformation@advanzpharma.com</a></td>
<td>+1890 25 24 73</td>
<td>+0035316971641</td>
</tr>
<tr>
<td>Essential-Healthcare Ltd</td>
<td>Carbinazole 5mg Tablets &amp; Carbinazole 20mg Tablets</td>
<td><a href="mailto:pv@essential-healthcare.co.uk">pv@essential-healthcare.co.uk</a></td>
<td>+44(0)1277 286 199</td>
<td>+44 (0)1733 72 70 30</td>
</tr>
</tbody>
</table>

**Company contact point**

<table>
<thead>
<tr>
<th>Company name</th>
<th>Name of contact person</th>
<th>Contact Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amdipharm Limited</td>
<td>Dr. Anju Agarwal, Head of Drug Safety</td>
<td>E-mail: <a href="mailto:anju.agarwal@concordiaRx.com">anju.agarwal@concordiaRx.com</a> Telephone Number: +44 208 588 9225</td>
</tr>
<tr>
<td>Essential-Healthcare Ltd</td>
<td>Niket Shah (Director)</td>
<td>E-mail: <a href="mailto:niket.shah@essential-healthcare.co.uk">niket.shah@essential-healthcare.co.uk</a> Telephone number: +44 1277 286 199</td>
</tr>
</tbody>
</table>

On behalf of all MAHs,
Signed by:

[Signature]

Dr. Anju Agarwal
Head of Drug Safety
Amdipharm Limited